Comparison of Adverse Event Risks in Randomized Controlled Trials with Varying Follow-Up Times and Competing Events: Results from an Empirical Study-Reference-Cited by-同舟云学术

Comparison of Adverse Event Risks in Randomized Controlled Trials with Varying Follow-Up Times and Competing Events: Results from an Empirical Study

Published:2022-12-12 Issue: Volume: Page:1-14
ISSN:1946-6315
Container-title:Statistics in Biopharmaceutical Research
language:en
Short-container-title:Statistics in Biopharmaceutical Research

Author:

Rufibach Kaspar¹,Stegherr Regina²,Schmoor Claudia³,Jehl Valentine⁴,Allignol Arthur⁵,Boeckenhoff Annette⁶^ORCID,Dunger-Baldauf Cornelia⁴,Eisele Lewin⁷,Künzel Thomas¹,Kupas Katrin⁸,Leverkus Friedhelm⁹,Trampisch Matthias¹⁰,Zhao Yumin¹¹,Friede Tim¹²^ORCID,Beyersmann Jan²,

Affiliation:

1. F. Hoffmann-La Roche, Basel, Switzerland

2. Institute of Statistics, Ulm University, Ulm, Germany

3. Clinical Trials Unit, Faculty of Medicine and Medical Center, University of Freiburg, Freiburg, Germany

4. Novartis Pharma AG, Basel, Switzerland

5. Merck KGaA, Darmstadt, Germany

6. Bayer AG, Wuppertal, Germany

7. Janssen-Cilag GmbH, Neuss, Germany

8. Bristol-Myers-Squibb GmbH & Co. KGaA, München, Germany

9. Pfizer, Berlin, Germany

10. Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany

11. Eli Lilly and Company, Indianapolis, IN